Gary Brecka’s Longevity Protocol
About Gary Brecka
Evidence Rating Key
Evidence Ratings
โ โ โ โ โ Good evidence
โ โ โ โโ Moderate/mixed
โ โ โโโ Weak/anecdotal
โ โโโโ Brecka framework only
๐งฌ Methylation Support (Core Stack)
Brecka’s most distinctive recommendations โ bioavailable forms required if you carry MTHFR variants.
| Supplement | Form / Dose | Purpose | Evidence |
|---|---|---|---|
| Methylfolate (5-MTHF) | 400โ1,000 mcg/day1 | Bypasses MTHFR enzyme; DNA methylation, homocysteine control | โ โ โ โ โ |
| Methylcobalamin (B12) | 1,000โ5,000 mcg/day | Methyl-donor; nerve function; pairs with methylfolate | โ โ โ โ โ |
| B6 (P5P form) | 25โ50 mg/day | Active form; enzyme cofactor in methylation cycle | โ โ โ โโ |
| TMG (Trimethylglycine) | 1,000โ3,000 mg/day | Betaine; alternate methyl donor; lowers homocysteine2 | โ โ โ โ โ |
๐ Foundational Daily Supplements
| Supplement | Dose | Purpose | Evidence |
|---|---|---|---|
| Vitamin D3 + K2 | 5,000โ10,000 IU D3 / 200 mcg K2 | Immune, bone, testosterone support; K2 directs calcium | โ โ โ โ โ |
| Omega-3 (fish oil) | 2โ4 g EPA+DHA/day | Cardiovascular, inflammation, brain | โ โ โ โ โ |
| Magnesium Glycinate | 400 mg/day (evening) | Sleep, muscle relaxation, 300+ enzymatic reactions | โ โ โ โ โ |
| Zinc | 25โ30 mg/day | Testosterone, immune, wound healing; often depleted | โ โ โ โ โ |
| Reduced Glutathione | 500 mg/day (or liposomal) | Master antioxidant; detoxification3 | โ โ โ โโ |
| CoQ10 (Ubiquinol) | 200โ400 mg/day | Mitochondrial energy; ubiquinol form preferred over 40 | โ โ โ โ โ |
| Creatine | 5 g/day | Muscle, brain energy, one of Brecka’s “non-negotiables” | โ โ โ โ โ |
| Collagen Peptides | 10โ20 g/day | Joint, skin, connective tissue; with Vitamin C | โ โ โ โโ |
๐ Lifestyle Protocols
Brecka’s lifestyle stack is arguably as important as his supplements. These are the protocols he credits for transformative health changes.
โ โ โ โ โ
30g protein within 30 minutes of waking โ 30 minutes steady-state cardio (Zone 2, 130โ135 bpm). Brecka claims this sets cortisol rhythm and stabilises blood sugar all day. The protein timing component is debated, but Zone 2 cardio evidence is strong.4
โ โ โ โ โ
50โ60ยฐF water, 2โ5 minutes, 3โ5x/week. Protocol: post-workout for recovery, or morning for epinephrine/dopamine boost. Aligns with Huberman’s cold exposure framework.5
โ โ โ โโ
Nasal breathing exclusively; COโ tolerance training (Bohr effect). Brecka claims nasal breathing alone can transform HRV and Oโ utilisation. Patrick McKeown collaboration. Some evidence, lacks large-scale RCTs.6
โ โ โโโ
Barefoot contact with earth 20โ30 min/day. Claims electron transfer reduces inflammation. Evidence is preliminary (small studies, low quality). Brecka calls this foundational; mainstream consensus remains skeptical.
โ โ โ โโ
Via 10X Health System panel or 23andMe raw data. If C677T or A1298C variant present, standard (synthetic) B vitamins cannot be utilised โ switch to methylated forms. This is Brecka’s central intervention. MTHFR variants are common (~40% population carry one). Critics note Brecka overstates pathogenicity of heterozygous variants.7
โ ๏ธ Evidence Controversies
- MTHFR overreach: Brecka attributes a very wide range of conditions to MTHFR variants. Most geneticists consider heterozygous MTHFR clinically low-risk. Homozygous C677T does meaningfully raise homocysteine.
- Grounding: Weakest evidence of his stack. Not well-supported by peer-reviewed literature.
- Credential positioning: Brecka presents as a scientist but is not a licensed medical professional. His mortality data claims are not independently verified.
- Dana White result: Widely cited but is a single anecdote, not a controlled trial.
Footnotes
- Dosing highly variable by genotype. Homozygous C677T may require higher doses under physician guidance.
- TMG as betaine: one of the best-evidenced homocysteine-lowering interventions independent of MTHFR status.
- Oral glutathione absorption debated; liposomal or IV forms have better bioavailability data.
- Zone 2 cardio evidence: independent of Brecka โ see Attia’s protocol page for in-depth discussion.
- Cold exposure aligns with Huberman’s dopamine/norepinephrine framework โ see Huberman protocol page.
- Patrick McKeown “Oxygen Advantage” method โ some HRV evidence exists, needs replication.
- MTHFR prevalence: ~10โ15% homozygous C677T in European populations; heterozygous ~40%. Clinical significance graded accordingly.
Changelog
- Mar 2026 โ Page created. Sources: podcast interviews, 10X Health System, Joe Rogan #1950, Diary of a CEO.
Sources
Compare Other Protocols
Note: Brecka’s methylation-first approach differs significantly from Attia (biomarker-led) and Sinclair (NAD/sirtuin focus). Brecka and Sinclair both use TMG; Attia does not prioritise it.
Stay updated on protocol changes
We track updates from Brecka’s podcasts and 10X Health releases. Changes logged above.
๐ Protocol Change Log
March 2026 โ Protocol page updated with latest publicly shared information.
